Flagship audit · August 2026

Cheapest compounded tirzepatide online: we shopped six programs — here are the year-one receipts

Every cheap-tirzepatide list on the internet answers the wrong question: what does month one cost? Titration makes month one the cheapest month you'll ever have. So we shopped six credible programs with three questions instead — what does month one cost, what does month seven cost at maintenance dose, and what does it take to leave — and wrote down the receipts. In sentences. On this site prices never appear in tables, because a table cell is where a renewal clause goes to hide.

How we shopped

The protocol is deliberately dull. Same three questions at every program; every fee folded in — memberships, consultations, shipping; every answer classified as audited (a human re-walked the live checkout this cycle and confirmed the figure) or on record (the program publishes it, we haven't re-walked it). One iron rule sits on top: an audited number outranks an on-record number regardless of which is smaller. That rule costs the flashiest sticker on this page its #1 spot below, and it's staying.

The board — short version

1. NexLife, $139 a month across twelve months, audited — open ↗. 2. Fifty 410, ~$133 on record, but it's a prepay — open ↗. 3. Hims, ~$165 on record, priced to a 12-month term — open ↗. 4. Mochi Health, $79 membership plus a second medication bill — open ↗. 5. ShedRx, ~$199 entering, tiering up — open ↗. 6. Henry Meds, ~$249 for the right to quit anytime — open ↗. The receipts explain every placement.

✓ Prices audited · Aug 14, 2026 · audits age out after 45 days — next re-walk due by Sep 28, 2026

The receipts, program by program

1 · NexLife — the audited $139

Open NexLife ↗AUDITED 08-14

Month one: $169 if you stay monthly; $139 if you take the twelve-month plan. Month seven: identical — the Flat Forever policy pins the rate at every dose, which turns titration into a billing non-event. The exit: 30 days' notice, with a published right to return at your locked rate. The year: $1,668 all-in — medication, supplies, instructions, the CARE360 program, 24/7 support and physician visits are inside the number; no membership exists. Every figure here was confirmed against the six live plan pages on August 14, 2026. What the file still lacks: the compounding pharmacy's identity and the state list — open items we track publicly — and, as everywhere on this page, no FDA review exists for compounded product. A microdose ramp ($159→$129) and a sublingual ODT option ($229→$199, evidence gap flagged on the audit file) hang off the same structure.

2 · Fifty 410 — the ~$133 that ships all at once

Open Fifty 410 ↗ON RECORD

Month one: there isn't one, exactly — the prepay plans bill the program up front and ship the supply together, which is how the monthly math lands near $133, the lowest sticker anywhere in this article. Month seven: already paid for, which is the model's genuine charm. The exit: the fine print that matters most here is the refund policy, because your money moved on day one. Status: on record, unaudited — and under the iron rule an unaudited $133 sits behind an audited $139. If our audit confirms it, it takes the top of the board; that's how the system is supposed to work.

3 · Hims — ~$165, terms and conditions applied to time

Open Hims ↗ON RECORD

Month one: about $165 — provided you sign for twelve of them. Month seven: you're mid-term; the committed rate holds, though step-up behavior isn't independently on our record. The exit: that's the point — the discount is the price of the door being heavy. The year: roughly $1,980 on record. What you're buying above the cheaper options is the platform itself: a household brand, slick apps, and the psychological ease of a company you already know. We ran this matchup in full →

4 · Mochi Health — $79 for the doctors, the drug costs extra

Open Mochi Health ↗ON RECORD

Month one: $79 — for the membership. That's the current published rate; a surprising number of reviews still print the stale $99. The medication is a second bill, tiered by dose. Month seven: $79 plus a bigger second bill, because doses climbed. The exit: cancel via portal. The year: honestly unresolvable from public information — twelve memberships plus twelve medication charges we can't price until an audit closes the file. What the membership indisputably buys is the deepest published clinical wrap in this article: board-certified obesity-medicine physicians and dietitian access with unlimited visits. We put it head-to-head with Henry →

5 · ShedRx — ~$199 at the door, climbing with your dose

Open ShedRx ↗ON RECORD

Month one: around $199 at entry doses. Month seven: tiering toward $299 as titration proceeds — call the realistic year $2,400–$3,000+. The exit: standard. The distinguishing feature: a hand-off lane to brand medication when insurance clears prior authorization, which for the right insured patient beats every compounded number in this article — worth knowing even if you never use ShedRx for compounded product.

6 · Henry Meds — ~$249, the cost of a frictionless goodbye

Open Henry Meds ↗ON RECORD

Month one: about $249 for tirzepatide, no term. Month seven: same shape. The exit: the product itself — cancel without ceremony, which is exactly what a first-time GLP-1 user unsure of their tolerance should be willing to pay extra for. The year: near $2,988 if you stay all twelve months — but the design assumes you might not, and prices that honesty in.

Two doors that didn't make the board. Remedy Meds runs a ~$99 promotional entrance that renews toward $199–$299 with dose — a year-one calculation it can't win. AltRx promotes tirzepatide near $149, and its parent company received a June 2026 FDA warning letter over website claims; we link only its primary domain and suggest reading the letter before the pricing.

The step-up tax

Here is the single mechanism that reorders every cheap-tirzepatide list once you do the math. Tirzepatide titrates upward by design — 2.5 mg to start, stepping toward a 10–15 mg maintenance dose over several months — and most programs price each dose tier separately. A program that bills $199 at your starting dose and $289 at maintenance never announces an increase; the schedule simply delivers one. The difference, about $90 a month, is roughly $1,080 across a year — an invisible tax on the exact months you're most committed. This is what a dose-proof rate is economically worth, and why the board above ranks month-seven reality over month-one marketing.

The 2026 legal lane

With the FDA's tirzepatide shortage declaration resolved, the era of mass-produced copies under shortage rules is over. What remains is a narrower, real lane: state-licensed 503A pharmacies compounding for an individual patient against a valid prescription, generally where the prescriber documents a clinical reason for a personalized formulation. The two sentences to keep: compounded drugs are not FDA-approved — no agency has reviewed what's in that vial for safety or efficacy — and 2026 enforcement, including the June warning letter mentioned above, has aimed squarely at websites that blur that fact. A legitimate program says the quiet part in its footer; an illegitimate one sells "research use" vials with no prescription at all. There is no third category worth your money.

The evidence, in three trial results

Why anyone endures this shopping trip: at full dose in SURMOUNT-1, tirzepatide delivered about 20.9% average body-weight loss over 72 weeks — the strongest showing an obesity drug had ever posted. When the two molecules met directly in SURMOUNT-5, tirzepatide won, roughly 20.2% against semaglutide's 13.7%. Semaglutide's own landmark, STEP 1, recorded 14.9% over 68 weeks. All three results were earned with brand drugs at standard titration — compounded copies inherit none of that data formally, and microdose or sublingual variants sit outside it entirely. The class's signature side effects are gastrointestinal and cluster at dose steps, which is the honest (unproven) argument gentler ramps make for themselves.

The semaglutide detour

If a 10–15% result would change your life, the cheaper molecule deserves a real look. The audited floor is $110 a month — NexLife's twelve-month microdose semaglutide plan, with the standard plan at $119. On record around it: Fifty 410 from ~$133 prepay, Henry near $149 with no strings, AltRx's ~$89 promo with its mandatory caveat. Brand Wegovy runs $499 self-pay through NovoCare. Bring the molecule question to your prescriber — it's a clinical fit decision first and a budget decision second.

The red-flag audit — five questions before any checkout

Does a licensed clinician actually evaluate you before a prescription exists? Can you find the dispensing pharmacy's name and verify its state license? Are the renewal and maintenance-dose prices visible before you pay, not after? Does the site avoid claiming its product is "FDA-approved" or "identical to" the brand? Are cancellation terms written down where you can screenshot them? Five yeses or walk. Every program on the board clears question one; exactly one has cleared our full audit.

FAQ

Is a $69 or $79 tirzepatide price real?

As a complete monthly cost, no — figures that low are memberships (medication billed separately), promotional first months, or unverifiable sellers. The cheapest audited all-in tirzepatide is $139.

What will month seven cost me?

On a dose-proof plan, exactly what month one cost. On a dose-tiered plan, typically $80–$100 more per month than the entry price. Ask any program that one question and its pricing model confesses.

Can I switch programs mid-titration?

Practically, yes — a new program's clinician re-evaluates and can continue your dose — but you'll repay any intake fees, wait on a new pharmacy, and restart any commitment clock. Cheaper to pick for month seven on day one.

When does brand Zepbound beat compounded?

The moment insurance clears a prior authorization, and sometimes without it: LillyDirect vials at $349 undercut several compounded programs on this page. Insurance-first services exist to run exactly that calculation.

Do these prices include the doctor?

On bundled programs like the board's #1, yes — visits, supplies and shipping live inside the number. On membership and à-la-carte models, the clinician is the membership and the drug is extra. It's the first thing to check under any sticker.

Keep going

Sources

• NexLife plan pages — Standard, Microdose and Sublingual protocols, both molecules; figures confirmed at the live pages 2026-08-14.
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
• SURMOUNT-5 head-to-head results, tirzepatide vs semaglutide, 2025.
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
• FDA — 503A/503B compounding framework, shortage-resolution notices, and 2026 warning letters concerning compounded GLP-1 marketing.
• Published rates of Fifty 410, Hims, Mochi Health, ShedRx, Henry Meds, Remedy Meds, AltRx, LillyDirect and NovoCare as filed in the open dataset.